对于高血压而言,脏缺血是治疗高血压的方法之一
Naomi D L Fisher1,2, Ajay J Kirtane3,4,5
1Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA, USA. nfisher@bwh.harvard.edu.
Nature reviews. Cardiology
|January 1, 2025
概括
脏缩 (RDN) 为高血压提供了一种新的程序性治疗方法,独立于药物坚持. 最近FDA对RDN系统的批准标志着在治疗各种高血压病例方面取得了重大进展.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 全球范围内高血压的患病率正在上升,尽管有众多的医学疗法,但控制率正在下降.
- 程序性干预,如脏剥皮 (RDN),为药物提供了替代方案,绕过了粘附问题.
- 在过去的二十年里,RDN已经发生了显著的进化,其设备,技术和试验设计都得到了改进.
研究的目的:
- 审查目前高血压控制的现状和脏缩 (RDN) 的演变.
- 总结支持RDN在高血压治疗中的有效性和安全性的证据.
- 为患者选择和实施RDN程序提供实际指导.
主要方法:
- 早期研究和随机临床试验对脏缩 (RDN) 的综述.
- 模拟控制的临床试验分析,证明RDN的有效性和安全性.
- 审查国际声明和RDN实施的指导方针.
主要成果:
- 两种不同的RDN系统 (射频和超声波) 在2023年底获得FDA批准.
- 临床试验证明了RDN在高血压的整个频谱中的有效性和安全性.
- 在患有轻度,中度和抗性高血压的患者中,RDN是有效的,包括那些服用最少药物的患者.
结论:
- 脏缩 (RDN) 是一种成熟的高血压干预疗法,有强有力的临床证据支持.
- 美国食品和药物管理局的批准标志着一个重要的里程碑,使得RDN在不同患者群体中得到更广泛的应用.
- 成功实施RDN需要一个多学科的高血压团队和与患者共享的决策.
更多相关视频
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
4.6K
11:08Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
Published on: February 14, 2018
10.1K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299
01:25Antihypertensive Drugs: Direct Renin Inhibitors
437
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
437
01:16Antihypertensive Drugs: Action of Diuretics
566
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
566
01:17Antihypertensive Drugs: Action of β1 Blockers
258
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
258
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
373
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
373
01:23Antihypertensive Drugs: Vasodilators
426
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
426